TFF3 and breast carcinoma: In total 27 (85%) of breast carcinoma cases that have complete response to neoadjuvant therapy have shown either no expression (Fig. 6a) or low expression of TFF3 in neoplastic cells at pre-neoadjuvant biopsies (Fig. 6c).